Retatrutide vs Ozempic: Evidence on HbA1c Reduction You Can Use for Decision Making

Glycemic reduction is the central question for clinicians choosing between these therapies. In separate phase 3 data, retatrutide has demonstrated meaningful HbA1c reductions across dose groups, while Ozempic’s HbA1c effects come from long-standing diabetes trials. Specifically, high-dose retatrutide yielded larger average HbA1c reductions than early retatrutide doses, with numeric improvements observed across trials, but these results come from different study designs and populations, so direct comparisons should be interpreted with caution.

In the Phase 2 TRANSCEND-T2D-1 trial (retatrutide vs placebo in adults with type 2 diabetes), HbA1c reductions ranged from 1.69 to 1.94 percentage points at 40 weeks across retatrutide doses of 4 mg, 9 mg, and 12 mg, compared with a placebo reduction of 0.81 percentage points. Weight change accompanied these glucose outcomes, with 11.5% to 15.3% weight loss at the corresponding retatrutide doses. These results illustrate dose-dependent improvements in HbA1c and body weight, but they are not head-to-head against semaglutide.

The more recent TRIUMPH-2 Phase 3 program reports HbA1c reductions with retatrutide at 80 weeks in adults with type 2 diabetes and obesity. Across the 4 mg, 9 mg, and 12 mg dose groups, average HbA1c reductions were 1.4%, 1.6%, and 1.5%, respectively, with baseline HbA1c around 7.7%. In weight terms, participants receiving 4 mg, 9 mg, and 12 mg lost about 29.8 pounds (12.7%), 45.4 pounds (19.1%), and 49.6 pounds (20.8%), versus placebo. Among individuals with a baseline BMI of 35 kg/m2 or higher who received 12 mg, weight loss reached an average of 60.8 pounds (23.4%), and by the end of the study 59.5% no longer met obesity criteria. These trials also report substantial improvements in several cardiovascular risk factors alongside weight loss and glycemic control.

For context, Ozempic (semaglutide) has shown HbA1c reductions in the range of about 1.0 to 1.5 percentage points in diabetes trials, depending on dose and baseline levels. The Wegovy dose of semaglutide (2.4 mg weekly, used in obesity studies) typically yields around 14.9% weight loss at 68 weeks in obesity-focused trials, with different HbA1c effects in diabetes populations. Comparisons across these studies are indirect and should account for differences in baseline HbA1c, duration, and patient characteristics.

Weight loss outcomes are a major differentiator in trial reports. In TRANSCEND-T2D-1, retatrutide produced substantial weight reductions alongside HbA1c improvements, with 11.5% to 15.3% weight loss at 40 weeks across doses. By contrast, in trials of semaglutide (the active ingredient in Ozempic/Wegovy), weight loss ranges up to about 14.9% at higher obesity-focused doses over 68 weeks. It is important to note that the duration and study populations differ between these programs, so direct cross-trial comparisons should be interpreted with caution.

Another lens on weight change comes from retatrutide’s Phase 3 data, where higher-dose regimens yielded the greatest reductions. For example, in TRIUMPH-2, retatrutide at 12 mg produced the largest sustained weight losses, with substantial absolute pounds shed over the treatment period. These results underscore the potential for retatrutide to achieve greater weight reduction than current Ozempic regimens in controlled trial settings, while acknowledging that these are not head-to-head comparisons.

Side effect profiles are an integral part of interpreting efficacy. In TRANSCEND-T2D-1, retatrutide showed nausea rates that varied by dose, with higher-dose groups experiencing more GI symptoms. Retatrutide nausea ranged up to about 28% in the Phase 3 TRIUMPH-2 program, across the 4 mg, 9 mg, and 12 mg cohorts. Ozempic data from various trials have reported higher nausea rates in some contexts, including about 44% in certain comparisons, though exact figures depend on dose, population, and trial design. Across both drugs, common GI symptoms include nausea, diarrhea, vomiting, and abdominal discomfort, typically most prominent during dose escalation and often improving over time as patients acclimate.

Phase 3 TRIUMPH-2 also reported a broader safety picture. Discontinuation due to adverse events occurred in 3.8% (4 mg), 11.6% (9 mg), and 7.7% (12 mg) of retatrutide participants, versus 4.9% in placebo. These figures suggest a tolerability profile that, while dependent on dose, remains manageable for many patients, particularly when balanced against notable efficacy in weight and HbA1c reductions.

Serious adverse events and class-wide safety considerations apply to both medications, including warnings about pancreatitis and thyroid tumors based on animal data. Decisions about starting either therapy should consider individual risk factors, history, and close medical supervision, especially during dose escalation.

Beyond HbA1c and weight, retatrutide has shown meaningful improvements in several cardiovascular risk factors in TRIUMPH-2. The highest dose, relative to baseline, delivered reductions of 39.5% in triglycerides, 19.6% in non-HDL cholesterol, a 10.8 mmHg drop in systolic blood pressure, and a 58.3% decrease in high-sensitivity C-reactive protein (hsCRP). In addition, retatrutide produced a waist circumference reduction of 6.7 inches (16.9 cm). While these findings are encouraging for a broader metabolic benefit, long-term cardiovascular outcomes data are not yet established for retatrutide, and these results come from trials not designed to prove cardiovascular risk reduction the way Ozempic’s SELECT program was designed to do.

Ozempic’s cardiovascular benefits are supported by dedicated outcome data in adults with established cardiovascular disease, contributing to a 20% relative risk reduction in major adverse cardiovascular events in SELECT. Retatrutide has not yet completed a dedicated cardiovascular outcomes program, though its metabolic effects are substantial and ongoing Phase 3 work aims to address longer-term outcomes.

Regulatory prospects for retatrutide are advancing. Lilly has indicated plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first quarter of 2027. Health Canada timelines are expected to follow after FDA actions, though exact timing can vary by country. In the near term, Ozempic remains the available option for patients with type 2 diabetes or obesity-related indications, with established prescribing pathways and insurance coverage in many regions.

Readers should be aware that, as of now, no published head-to-head trial directly comparing retatrutide with Ozempic has reported results. The TRANSCEND-T2D-2 study is an ongoing Phase 3, open-label trial designed to compare retatrutide directly against semaglutide with HbA1c changes measured at 80 weeks. Results are not yet available. This ongoing study is expected to clarify relative efficacy, but until results are published, conclusions about direct superiority remain provisional and based on indirect, cross-trial evidence.

What does all this mean for treatment decisions today? For patients needing immediate treatment and wanting an approved option with established use, Ozempic remains the practical choice. Its regulatory status, broader safety data, and current availability make it the go-to for many people living with type 2 diabetes, with proven cardiovascular risk reduction in the right populations and established insurance coverage in many settings.

Retatrutide offers compelling potential for greater HbA1c reductions and heavier weight loss in trials, especially at higher doses, along with favorable signals on several metabolic risk factors. However, until it receives regulatory approval and direct comparative data, clinicians should frame retatrutide as a promising future option rather than a substitute for current standard therapy. For patients who can wait and who meet trial eligibility or who seek maximum weight and glycemic benefit, retatrutide represents a meaningful horizon—subject to trial enrollment, regulatory review, and post-approval access logistics.

Cost considerations also influence decision-making. Ozempic currently has a defined price and insurance pathways in many markets, with potential manufacturer assistance programs. Retatrutide pricing will be determined after regulatory approval. Until then, patients should discuss current options with their healthcare providers and consider ongoing monitoring, lifestyle measures, and adherence plans as essential companions to pharmacotherapy.

For patients in Canada, access considerations reflect regulatory status and provincial formularies. Ozempic is approved for type 2 diabetes and is covered in many provinces with criteria; private insurance often contributes to coverage. Retatrutide’s Canadian availability will hinge on Health Canada approval and subsequent coverage negotiations, which typically follow FDA approval but may lag by months. Given current timelines, many patients may continue with Ozempic while watching for new options as regulatory decisions unfold.

Frequently Asked Questions

Is retatrutide approved for type 2 diabetes?

No. Retatrutide is not FDA-approved and remains investigational, with Phase 3 trials in progress.

Is retatrutide more effective than Ozempic for lowering HbA1c?

Current evidence does not prove this. Trials for retatrutide are not head-to-head against Ozempic; a dedicated head-to-head study (TRANSCEND-T2D-2) is underway, with results pending.

Does retatrutide cause more weight loss than semaglutide?

Placebo-controlled retatrutide trials show substantial weight loss (up to about 24.2% at 48 weeks in some regimens), while semaglutide trials show up to about 14.9% weight loss at higher obesity-focused doses. Direct comparison is not established in head-to-head trials.

Can I switch from Ozempic to retatrutide when it becomes available?

Currently, retatrutide is not approved for routine prescription, so switching outside a trial is not a standard option. Decisions should be guided by a healthcare provider as new data and approvals emerge.

What about cardiovascular or kidney disease outcomes?

Ozempic has FDA-approved indications related to cardiovascular risk reduction and kidney protection in certain patients with type 2 diabetes. Retatrutide has not yet completed long-term outcomes trials for these indications.

References and Data Sources

• TRIUMPH-2 Phase 3 program data for retatrutide, including HbA1c reductions and weight loss at 80 weeks, with additional cardiovascular risk factor improvements reported (triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference, hsCRP).
• TRANSCEND-T2D-1 trial results (Lancet-style reporting) showing HbA1c reductions of 1.69–1.94 percentage points and weight loss of 11.5–15.3% at 40 weeks for retatrutide across dose groups (placebo-controlled).
• Lilly press releases and trial summaries noting a possible 1.6% average HbA1c reduction and up to 40% achieving HbA1c <5.7% at 80 weeks in TRIUMPH-2, with detailed dose-specific numbers.
• Context on Ozempic (semaglutide) efficacy data from obesity and diabetes trials, including Wegovy dosing and weight loss outcomes (e.g., up to 14.9% weight loss at 68 weeks in Wegovy trials) and cardiovascular outcomes data from SELECT.
• Regulatory timelines: Lilly statements indicating a planned Biologics License Application submission in Q1 2027; Health Canada timelines are expected to follow FDA actions.